24 research outputs found
ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠΉ Π²ΡΠ±ΠΎΡ Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΠΎΡΠΌ Π°ΠΊΠ½Π΅
Modern data of the acne pathogenesis, including the role of Propionibacterium acnes in the early stages of the acne formation and their provocative role in the development of the inflammatory process are presented. Priority importance of topical retinoids and combination products containing fixed combinations adapalene with benzoyl peroxide or antibiotic clindamycin in the acne treatment are shown. There are presented the facts of the effectiveness of Clenzit gel (adapalene 0.1%) and Clenzit-C (adapalene 0.1% and clindamycin phosphate 1.0%) and an algorithm for the choice of drug depending on clinical and morphological features of the skin process that allows to optimize the treatment of patients with various forms of acne.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π°ΠΊΠ½Π΅, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ P. acnes Π½Π° ΡΠ°Π½Π½ΠΈΡ
ΡΡΠ°ΠΏΠ°Ρ
ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²ΡΡΡΠΏΠ°Π½ΠΈΠΉ ΠΈ ΠΈΡ
ΠΏΡΠΎΠ²ΠΎΡΠΈΡΡΡΡΠ΅ΠΉ ΡΠΎΠ»ΠΈ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΠΈ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ΄ΠΎΠ² ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°Π΄Π°ΠΏΠ°Π»Π΅Π½Π° Ρ Π±Π΅Π½Π·ΠΎΠΈΠ»Π° ΠΏΠ΅ΡΠΎΠΊΡΠΈΠ΄ΠΎΠΌ ΠΈΠ»ΠΈ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠΌ ΠΊΠ»ΠΈΠ½Π΄Π°ΠΌΠΈΡΠΈΠ½ΠΎΠΌ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π³Π΅Π»Π΅ΠΉ ΠΠ»Π΅Π½Π·ΠΈΡ (Π°Π΄Π°ΠΏΠ°Π»Π΅Π½ 0,1%) ΠΈ ΠΠ»Π΅Π½Π·ΠΈΡ-Π‘ (Π°Π΄Π°ΠΏΠ°Π»Π΅Π½ 0,1% ΠΈ ΠΊΠ»ΠΈΠ½Π΄Π°ΠΌΠΈΡΠΈΠ½Π° ΡΠΎΡΡΠ°Ρ 1,0%) Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΠΊΠ½Π΅ ΠΈ Π°Π»Π³ΠΎΡΠΈΡΠΌ Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΊΠΎΠΆΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΎΠΏΡΠΈΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Π°ΠΊΠ½Π΅
ΠΠΏΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠΌΠΈ ΠΈ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ Π°ΠΊΠ½Π΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½
Ural Research Institute of Dermatovenerology and Immunopathology, Ekaterinburg, Russia Shherbakova street 8, 620076, Ekaterinburg, Russia Objective: assessment of the clinical efficacy and safety of the treatment of patients suffering from acne of different forms of severity with the use of isotretinoin (Acnecutan). Materials and methods. Thirty-two patients with acne underwent treatment and made up 3 groups: 11 patients with the moderate to severe form of acne, 12 patients with the severe form of acne, and 9 patients with acne conglobata. The Basic Acne Severity Index (BASI) was used to assess objective manifestations of the disease. Results: As a result of treatment, the BASI reduced in patients with moderate to severe acne from 25.1 Β± 1.6 to 1.5 Β± 0.7, in patients with severe acne - from 31.5 Β± 2.0 to 1.3 Β± 0.8, with acne conglobata - from 45.3 Β± 5.2 to 2.8 Β± 0.7. Adverse effects that were recorded (such as skin dryness and xerosis, cheilitis and retinoid dermatitis, increased ASAT and ALAT levels in the blood serum) were eliminated with the use of skin care products or by reducing the drug dose. Conclusion: The authors demonstrated high efficacy and safety of Acnecutan in the treatment of patients suffering from acne vulgaris.Π¦Π΅Π»Ρ. ΠΡΠ΅Π½ΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΠΊΠ½Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΈΠ·ΠΎΡΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ½ (ΠΠΊΠ½Π΅ΠΊΡΡΠ°Π½*). ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ 32 Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΠΊΠ½Π΅, ΡΠΎΡΡΠ°Π²ΠΈΠ²ΡΠΈΡ
3 Π³ΡΡΠΏΠΏΡ: 11 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ β ΡΠΎ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π°ΠΊΠ½Π΅, 12 β Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΈ 9 β Ρ ΠΊΠΎΠ½Π³Π»ΠΎΠ±Π°ΡΠ½ΡΠΌΠΈ Π°ΠΊΠ½Π΅. ΠΠ»Ρ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΡΡ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΎΠ±ΡΠ΅ΠΉ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠ³ΡΠ΅ΠΉ (ΠΠ’Π£). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΠ’Π£ ΡΠ½ΠΈΠ·ΠΈΠ»ΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠΌΠΈ Π°ΠΊΠ½Π΅ Ρ 25,1 Β± 1,6 Π΄ΠΎ 1,5 Β± 0,7 Π±Π°Π»Π»Π°, Ρ ΡΡΠΆΠ΅Π»ΡΠΌΠΈ Π°ΠΊΠ½Π΅ β Ρ 31,5 Β± 2,0 Π΄ΠΎ 1,3 Β± 0,8 Π±Π°Π»Π»Π°, Ρ ΠΊΠΎΠ½Π³Π»ΠΎΠ±Π°ΡΠ½ΡΠΌΠΈ Π°ΠΊΠ½Π΅ β Ρ 45,3 Β± 5,2 Π΄ΠΎ 2,8 Β± 0,7 Π±Π°Π»Π»Π°. ΠΡΠΌΠ΅ΡΠ°Π²ΡΠΈΠ΅ΡΡ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ (ΡΡΡ
ΠΎΡΡΡ ΠΊΠΎΠΆΠΈ ΠΈ ΡΠ»ΠΈΠ·ΠΈΡΡΡΡ
, Ρ
Π΅ΠΉΠ»ΠΈΡ ΠΈ ΡΠ΅ΡΠΈΠ½ΠΎΠΈΠ΄Π½ΡΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΈΡ, ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΠ‘Π’ ΠΈ ΠΠΠ’ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ) ΠΊΡΠΏΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌΠΈ ΡΡ
ΠΎΠ΄Π° Π·Π° ΠΊΠΎΠΆΠ΅ΠΉ ΠΈΠ»ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π΄ΠΎΠ·Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠΊΠ°Π·Π°Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΊΠ½Π΅ΠΊΡΡΠ°Π½ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π²ΡΠ»ΡΠ³Π°ΡΠ½ΡΠΌΠΈ Π°ΠΊΠ½Π΅
Π ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈΠ±ΠΎΠ»ΡΠ½ΡΠΌ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π»ΠΈΠΌΡΠΎΠΌΠ°ΠΌΠΈ ΠΊΠΎΠΆΠΈ
The authors analyzed the responses from directors of dermatovenerology institutions to a standardized questionnaire with questions
about recording patients with malignant cutaneous lymphomas, follow-up care, diagnostics, treatment of patients, cooperation
with experts in allied fields. They also revealed defects and problems in the organization of specialized medical aid for patients
with malignant cutaneous lymphomas in the territory of the Russian Federation, and developed prospective methods for improvement
of aid rendered to patients with malignant cutaneous lymphomas.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΎΡΠ²Π΅ΡΠΎΠ² ΡΡΠΊΠΎΠ²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ ΠΊΠΎΠΆΠ½ΠΎ-Π²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ Π½Π° ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ Π°Π½ΠΊΠ΅ΡΡ ΠΏΠΎ Π²ΠΎΠΏΡΠΎΡΠ°ΠΌ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π»ΠΈΠΌΡΠΎΠΌΠ°ΠΌΠΈ ΠΊΠΎΠΆΠΈ (ΠΠΠ), Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΠ½ΠΎΠΌΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅, ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΎ ΡΠΌΠ΅ΠΆΠ½ΡΠΌΠΈ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠ°ΠΌΠΈ. ΠΡΡΠ²Π»Π΅Π½Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ ΠΈ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ Π² ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΠΠ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΡΡ
Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠ΅ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠΌΠΎΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΠΠ
ΠΠ΅Π»ΡΠΌΠΈΠ½ΡΠΎΠ·Ρ ΠΈ ΠΏΡΠΎΡΠΎΠ·ΠΎΠΎΠ·Ρ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ
According to the statistics reports for 2005-2008, a reliable reduction in the intensive indices of lambliasis incidence rate in the
Sverdlovsk region as well as tendency towards a reduction in opisthorchosis and enterobiasis incidence rate was revealed. An
examination of 262 patients in the clinics of FGU UrNIIDViI revealed that the incidence of helminthic and protozoal invasions in
psoriatic patients was 44.1% while the incidence of allergic dermatoses was 32.3%. Blastocysts, intestinal amoebas, seatworms
as well as opisthorchid flukes in case of psoriasis dominated in terms of incidence. High prevalence of seatworms in adolescent
males and women of childbearing potential was discovered.ΠΠΎ Π΄Π°Π½Π½ΡΠΌ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΡΠ΅ΡΠ½ΠΎΡΡΠΈ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 2005-2008 Π³Π³. ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π‘Π²Π΅ΡΠ΄Π»ΠΎΠ²ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π»ΡΠΌΠ±Π»ΠΈΠΎΠ·ΠΎΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΎΠΏΠΈΡΡΠΎΡΡ
ΠΎΠ·ΠΎΠΌ ΠΈ ΡΠ½ΡΠ΅ΡΠΎΠ±ΠΈΠΎΠ·ΠΎΠΌ. ΠΡΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ 262 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅ Π€ΠΠ£ Β«Π£ΡΠΠΠΠΠΠΈΠΒ» Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π·Π°ΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ Π³Π»ΠΈΡΡΠ½ΠΎ-ΠΏΡΠΎΡΠΎΠ·ΠΎΠΉΠ½ΡΠΌΠΈ ΠΈΠ½Π²Π°Π·ΠΈΡΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 44,1%, Π°Π»Π»Π΅ΡΠ³ΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ - 32,3%. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΡΡΡΠΈΠΌΠΈ ΠΏΠΎ ΡΠ°ΡΡΠΎΡΠ΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΠ»ΠΈΡΡ Π±Π»Π°ΡΡΠΎΡΠΈΡΡΡ, ΠΊΠΈΡΠ΅ΡΠ½Π°Ρ Π°ΠΌΠ΅Π±Π°, ΠΎΡΡΡΠΈΡΡ,
Π° ΠΏΡΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π΅ - ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΠΈΡΡΠΎΡΡ
ΠΈ. ΠΡΡΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ Π·Π°ΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ ΠΎΡΡΡΠΈΡΠ°ΠΌΠΈ ΡΠ½ΠΎΡΠ΅ΠΉ-ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°
ΠΠ½Π°Π»ΠΈΠ· ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ² Π² ΠΎΠΊΠ°Π·Π°Π½ΠΈΠΈ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ ΠΏΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ Β«ΠΠ΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΒ»
Results of sampling epidemiological investigation of patients with dermatologic diseases, which sought treatment in the specialized Russian outpatient facilities over two-month period, and assessments of approaches to treatment of patients with atopic dermatitis, psoriasis and eczema are presented. Data of 2991 individual registration cards, which were filled out by the dermatovenerologists providing primary specialized care to patients in outpatient facilities of Perm, Samara and St. Petersburg, was analyzed. It was observed that women were prevalent among patients with dermatoses, and most of women and men were of working age (82.2 and 89.2% corresponding). The nosological structure of appealability consists of 25.6% patients with dermatose, psoriasis (14.5%), eczema (13.4%), seborrhea and acne (8.6%), atopic dermatitis (5.8%), and pyodermatitis (3.2%). Using standardized indexes for assessment it was discovered that among applied outpatients 80% persons, presented with atopic dermatitis, and 50% persons, presented with psoriasis, had moderate and severe appearances of dermatoses. In therapy of patients with atopic dermatitis, psoriasis and eczema, specialists used widely standard system treatment - topic glucocorticosteroid agents for external care.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π²ΡΠ±ΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΡ
ΡΡ Π·Π° Π΄Π²ΡΡ
ΠΌΠ΅ΡΡΡΠ½ΡΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄ Π² ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΡΠ΅ ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π ΠΎΡΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΈ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ 2991 ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΊΠ°ΡΡΡ, Π·Π°ΠΏΠΎΠ»Π½Π΅Π½Π½ΡΡ
Π²ΡΠ°ΡΠ°ΠΌΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ, ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΠΌΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΏΠΎΠΌΠΎΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Π² Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎ-ΠΏΠΎΠ»ΠΈΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡΡ
Π² Π³ΠΎΡΠΎΠ΄Π°Ρ
ΠΠ΅ΡΠΌΠΈ, Π‘Π°ΠΌΠ°ΡΠ΅ ΠΈ Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½Ρ, ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡΠ΅Π΅ ΡΠΈΡΠ»ΠΎ ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈ ΠΌΡΠΆΡΠΈΠ½ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΈΡΡ Π² ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ (82,2 ΠΈ 89,2% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΡΠΊΡΡΡΠ΅ ΠΎΠ±ΡΠ°ΡΠ°Π΅ΠΌΠΎΡΡΠΈ 25,6% ΡΠΎΡΡΠ°Π²Π»ΡΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ°ΠΌΠΈ, ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ (14,5%), ΡΠΊΠ·Π΅ΠΌΠΎΠΉ (13,4%), ΡΠ΅Π±ΠΎΡΠ΅Π΅ΠΉ ΠΈ Π°ΠΊΠ½Π΅ (8,6%), Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ (5,8%), ΠΏΠΈΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ (3,2%). ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ
ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ², ΡΡΠ΅Π΄ΠΈ ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΡΠΉ ΠΏΡΠΈΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ Π±ΠΎΠ»Π΅Π΅ 80% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π° ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ - Π±ΠΎΠ»Π΅Π΅ 50%, ΠΈΠΌΠ΅Π»ΠΈ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠ΅ ΠΈ ΡΡΠΆΠ΅Π»ΡΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ². Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, ΡΠΊΠ·Π΅ΠΌΠΎΠΉ ΠΈ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΡ ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, Π² Π½Π°ΡΡΠΆΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ - ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ
ΠΠΏΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ ΠΏΡΡΠ΅ΠΉ β ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π°ΠΏΡΠ΅ΠΌΠΈΠ»Π°ΡΡ
The article presents a brief description of Πpremilast β the target synthetic anti-inflammatory drug, which is representative of a new class of agents for the treatment of psoriasis and psoriatic arthritis. The efficiency and safety of the new drug in the treatment of patients with severe psoriasis are shown.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½Π° ΠΊΡΠ°ΡΠΊΠ°Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π°ΠΏΡΠ΅ΠΌΠΈΠ»Π°ΡΡ β ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Ρ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° ΡΡΠ΅Π΄ΡΡΠ² Π΄Π»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΡΡΡΠΈΡΠ°. ΠΠΎΠΊΠ°Π·Π°Π½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π° Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠΆΠ΅Π»ΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ
ΠΠΏΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΡΠΆΠ΅Π»ΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ
In this study was summarized the clinical monitoring of 6 patients with a vulgar severe psoriasis receiving a short course of Ustekinumab β antagonist of IL 12/23. Clinical monitoring demonstrated high efficiency of treatment with achievement of clinical remission and appreciable improvement in all patients; conservation of remission of psoriasis process till 6 months with regress of PASI more than 75 % from initial point in 5 from 6 patients; improvement of quality of life, absence of complications and adverse events during the treatment and the subsequent observation.ΠΠ±ΠΎΠ±ΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ 6 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΡΠ»ΡΠ³Π°ΡΠ½ΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΊΠΎΡΠΎΡΠΊΠΈΠΉ ΠΊΡΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π± (ΡΡΠ΅Π»Π°ΡΠ°) ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΡΠ²Π»ΡΡΡΠ΅Π³ΠΎΡΡ Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΎΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΊ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°ΠΌ -12, -23. ΠΠΎΠΊΠ°Π·Π°Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΡΠ΅Π»Π°ΡΠ° Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ Ρ Π²ΡΠ΅Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
; ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π΄ΠΎ 6 ΠΌΠ΅Ρ. Ρ ΡΠ΅Π³ΡΠ΅ΡΡΠΎΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠ° PASI Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Π½Π° 75% ΠΎΡ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ 5 ΠΈΠ· 6 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²; Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΠΉ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅Π³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
Π Π°Π·Π»ΠΈΡΠ½ΡΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΠΎΡΠΌΡ ΠΌΠ΅ΡΠΈΠ»ΠΏΡΠ΅Π΄Π½ΠΈΠ·ΠΎΠ»ΠΎΠ½Π° Π°ΡΠ΅ΠΏΠΎΠ½Π°ΡΠ° Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΠΊΠΎΠΆΠΈ
The article presents the results of the efficacy and safety assessment of the treatment of adult patients suffering from allergic dermatoses with different drug forms of methylprednisolone aceponate 0.1% (Advantan). The authors revealed high efficacy of the treatment of patients with atopic dermatitis and generalized eczema with the achievement of clinical remission and regression of the EASI index by 88.6-88.8% from the baseline level after three weeks of the drug administration; in patients with hand eczema after four weeks of treatment, and in patients with allergic dermatitis - after external treatment with methylprednisolone aceponate (MPA) 0.1% for two weeks; the patients' life quality improved after the treatment. Four weeks after the completion of the treatment, the skin of all the patients was nearly free from any eruptions while itching was negligible or absent. The efficacy of the differential administration of different drug forms of MPA 0.1% (Advantan) was demonstrated to localize eruptions in problem areas, on the skin in the area of the body and limbs, and according to particular features of clinical manifestations of dermatoses. The authors confirmed the safety of MPA 0.1% (Advantan) for the treatment of patients with allergic dermatoses as well as absence of any adverse effects in patients with AD, generalized eczema, hand eczema and allergic dermatitis within the aforesaid terms.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²Π·ΡΠΎΡΠ»ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π»Π»Π΅ΡΠ³ΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΈΠ»ΠΏΡΠ΅Π΄Π½ΠΈΠ·ΠΎΠ»ΠΎΠ½Π° Π°ΡΠ΅ΠΏΠΎΠ½Π°ΡΠ° 0,1% (ΠΠ΄Π²Π°Π½ΡΠ°Π½). Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ ΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠΉ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ ΠΈ ΡΠ΅Π³ΡΠ΅ΡΡΠΎΠΌ ΠΈΠ½Π΄Π΅ΠΊΡΠ° EASI Π½Π° 88,6-88,8% ΠΎΡ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΠΏΠΎΡΠ»Π΅ 3 Π½Π΅Π΄Π΅Π»Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°; Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ ΠΊΠΈΡΡΠ΅ΠΉ - ΠΏΠΎΡΠ»Π΅ 4 Π½Π΅Π΄Π΅Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ, Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ - ΠΏΠΎΡΠ»Π΅ Π½Π°ΡΡΠΆΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΌΠ΅ΡΠΈΠ»ΠΏΡΠ΅Π΄Π½ΠΈΠ·ΠΎΠ»ΠΎΠ½Π° Π°ΡΠ΅ΠΏΠΎΠ½Π°ΡΠΎΠΌ (ΠΠΠ) 0,1% Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 2 Π½Π΅Π΄Π΅Π»Ρ; Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. Π§Π΅ΡΠ΅Π· 4 Π½Π΅Π΄Π΅Π»ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΊΠΎΠ½ΡΠ°Π½ΠΈΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π²ΡΠ΅Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠΎΠΆΠ° ΠΎΡΡΠ°Π²Π°Π»Π°ΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΠΎΡ Π²ΡΡΡΠΏΠ°Π½ΠΈΠΉ, Π·ΡΠ΄ Π±ΡΠ» ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΠΌ ΠΈΠ»ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π». ΠΠΎΠΊΠ°Π·Π°Π½Π° ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΡΡΡ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠΎΡΠΌ ΠΠΠ 0,1% (ΠΠ΄Π²Π°Π½ΡΠ°Π½) ΠΏΡΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π²ΡΡΡΠΏΠ°Π½ΠΈΠΉ Π² ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΡΡ
Π·ΠΎΠ½Π°Ρ
, Π½Π° ΠΊΠΎΠΆΠ΅ ΡΡΠ»ΠΎΠ²ΠΈΡΠ°, ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ ΠΈ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠ². ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΠ 0,1% (ΠΠ΄Π²Π°Π½ΡΠ°Π½) Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π»Π»Π΅ΡΠ³ΠΎΠ΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°ΠΌΠΈ, ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ² ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ, ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠΉ ΡΠΊΠ·Π΅ΠΌΠΎΠΉ, ΡΠΊΠ·Π΅ΠΌΠΎΠΉ ΠΊΠΈΡΡΠ΅ΠΉ, Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ Π² ΡΠΊΠ°Π·Π°Π½Π½ΡΠ΅ ΡΡΠΎΠΊΠΈ